/Investor DB

Sixty Degree Capital — 2021 Investments

3 investments dated 2021 · listed companies and verified rows first · show all

Antios Therapeuticsantiostherapeutics.comin𝕏Nov 2021 · $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more

Arcellxarcellx.cominMar 2021

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in

BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in

Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSolasta VenturesSR One Capital Management+5 more

Clearcoverclearcover.comin𝕏Mar 2021 · $21M

Clearcover is an insurance company that simplifies auto insurance coverage selection and claims processing through a mobile-first platform, enabling fast claim payouts.

InsurTechChicago, US

Kyle Nakatsuji(Co-founder, President and CEO)inDerek Brigham(Co-founder)inJennifer Kemp(Executive Officer)Jennifer Crutchfield(Executive Officer)Norman Smagley(Executive Officer)in

BoardCynthia Hardy(Director)

Co-investors500 GlobalAmerican Family VenturesBetter Tomorrow VenturesGeodesic CapitalIA Capital GroupLightbank+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.